戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tional Classification and Grading System for Age-Related Maculopathy.
2       Matrix expansion is an early change in age-related maculopathy.
3  the International Classification System for Age-Related Maculopathy.
4  apparent independent birth cohort effect on age-related maculopathy.
5 d 10.32 (95% CI: 0.83, 128.58) for exudative age-related maculopathy.
6 s in macular function observed in ageing and age-related maculopathy.
7 o basal linear deposit, which accumulates in age-related maculopathy.
8  of these agents alone and in combination on age-related maculopathy.
9 amin supplement use affects the incidence of age-related maculopathy.
10 elation between smoking and the incidence of age-related maculopathy.
11 idence of some lesions associated with early age-related maculopathy.
12 shed on the relation of cigarette smoking to age-related maculopathy, an important cause of blindness
13  found a strong positive association between age-related maculopathy and age, when comparing particip
14 ells could be involved in the development of age-related maculopathy and age-related macular degenera
15                                              Age-related maculopathy and atherosclerotic cardiovascul
16  attributable to unmeasured risk factors for age-related maculopathy and limitations of risk factor m
17 rding to the International Classification of Age-related Maculopathy and Macular Degeneration.
18  the International Classification System for age-related maculopathy and stratified using the Rotterd
19 hat strong family determinants of lesions of age-related maculopathy are likely, less so for age-rela
20 ltivitamins, large reductions in the risk of age-related maculopathy are unlikely.
21 m to photographic evidence of early and late age-related maculopathy (ARM) among persons over age 40
22  participating in ARMA, a study of aging and age-related maculopathy (ARM) ancillary to the Health, A
23 h AMD were classified into two groups: early age-related maculopathy (ARM) and neovascular AMD.
24 roteinase 2 (MMP2) genes are associated with age-related maculopathy (ARM) in older women.
25 l consumption and the long-term incidence of age-related maculopathy (ARM) in people in the Beaver Da
26                                              Age-related maculopathy (ARM) is a leading cause of visu
27                                              Age-related maculopathy (ARM) is a leading cause of visu
28          Age-related macular degeneration or age-related maculopathy (ARM) is a major public health i
29                                              Age-related maculopathy (ARM) is an important cause of v
30                                              Age-related maculopathy (ARM) is one of the most common
31                          The pathogenesis of age-related maculopathy (ARM) is related to adverse vasc
32  and zinc and the 5-year incidence of early, age-related maculopathy (ARM) were investigated in a pop
33              Macular drusen are hallmarks of age-related maculopathy (ARM), but these focal extracell
34                                              Age-related maculopathy (ARM), or age-related macular de
35  Several dietary factors have been linked to age-related maculopathy (ARM), the early form of age-rel
36 de linkage studies of families affected with age-related maculopathy (ARM), we previously identified
37 ort barrier in aging and lesion formation in age-related maculopathy (ARM).
38 ) photostress test and the focal cone ERG in age-related maculopathy (ARM).
39 racellular lesions associated with aging and age-related maculopathy (ARM).
40 alth Study I who did not have a diagnosis of age-related maculopathy at baseline (1982).
41 rs, may explain changes in the prevalence of age-related maculopathy by age.
42 ere determined by using a modified Wisconsin Age-Related Maculopathy Grading Scale (a 6-level scale:
43  presence of AMD lesions using the Wisconsin Age-Related Maculopathy grading scheme.
44 c data were graded according to the Clinical Age-Related Maculopathy Grading System (CARMS) as grade
45 ographs that were graded using the Wisconsin Age-related Maculopathy Grading System (n = 5).
46  subject and were graded using the Wisconsin Age-Related Maculopathy Grading System (WARMGS).
47 tinal photographs according to the Wisconsin Age-Related Maculopathy Grading System and Airlie House
48 ion of AMD (assessed by use of the Wisconsin Age-Related Maculopathy Grading System on retinal photog
49                                The Wisconsin Age-Related Maculopathy Grading System was used to grade
50 dised grading classifications (the Wisconsin age-related maculopathy grading system, the internationa
51 graphic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System.
52 ages were graded for AMD using the Wisconsin Age-related Maculopathy Grading System.
53 graphic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System.
54 tinal photographs according to the Wisconsin Age-Related Maculopathy Grading System.
55 tinal photographs according to the Wisconsin Age-Related Maculopathy Grading System.
56 or ARM using a modification of the Wisconsin Age-Related Maculopathy Grading System.
57 hotographs graded using a modified Wisconsin Age-Related Maculopathy Grading System.
58 undus photographs according to the Wisconsin Age-Related Maculopathy grading system.
59 e volunteers was determined by the Wisconsin Age-Related Maculopathy Grading System.
60 color fundus photographs using the Wisconsin Age-related Maculopathy Grading System.
61 color fundus photographs using the Wisconsin Age-Related Maculopathy Grading System.
62 e number of people in the United States with age-related maculopathy is increasing in recent years be
63 cigarettes were more likely to develop early age-related maculopathy (odds ratio (OR) per 10 pack-yea
64 oretinopathy, subretinal neovascularization, age-related maculopathy, optic nerve disorders, and nerv
65 sible but nonsignificant 13% reduced risk of age-related maculopathy (relative risk = 0.87, 95 percen
66                                Patients with age-related maculopathy sensitivity 2 (ARMS2) risk allel
67 es into categories using a modified Clinical Age-Related Maculopathy Staging (CARMS) system.
68   Presence of AMD as defined by the Clinical Age-Related Maculopathy Staging system based on color fu
69 is of AMD was made according to the Clinical Age-Related Maculopathy Staging System.
70 elated Maculopathy Study (2001-2002) and the Age-Related Maculopathy Statin Study (2004-2006).
71                                              Age-related maculopathy status was determined by grading
72  individuals (346 sib pairs) from the Family Age Related Maculopathy Study (FARMS).
73 rom 2 studies: the Cardiovascular Health and Age-Related Maculopathy Study (2001-2002) and the Age-Re
74 ta from a previous GWS on AMD (FARMS [Family Age-Related Maculopathy Study]sample of 34 extended fami
75 ypes Complement Factor H (CFH) RS1061170 and Age Related Maculopathy Susceptibility 2 (ARMS2) RS37939
76 genotyped for 2 alleles associated with AMD, age-related maculopathy susceptibility 2 (ARMS2) and com
77 r age, sex, body mass index, smoking status, age-related maculopathy susceptibility 2 (ARMS2) and com
78 gous carriers of the A69S risk allele in the age-related maculopathy susceptibility 2 (ARMS2) gene (P
79  alleles of the complement factor H (CFH) or age-related maculopathy susceptibility 2 (ARMS2) genes,
80 rphisms in the complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genes.
81  the complement factor H (CFH)-rs1061170 and age-related maculopathy susceptibility 2 (ARMS2)-rs10490
82 ctions with complement factor H (rs1061170), age-related maculopathy susceptibility 2 (rs10490924), c
83 st prevalent amino acid substitutions in the age-related maculopathy susceptibility 2 gene linked to
84 4 risk alleles in a joint effect analysis of Age-Related Maculopathy Susceptibility 2 rs10490924 and
85 th the well-established AMD risk loci ARMS2 (age-related maculopathy susceptibility 2)-HTRA1 (HtrA se
86  loci in 7 genes [complement factor H (CFH), age-related maculopathy susceptibility 2/high-temperatur
87 en loci in 7 AMD genes [complement factor H, age-related maculopathy susceptibility 2/high-temperatur
88 02H in complement factor H (CFH) and A69S in age-related maculopathy susceptibility locus 2 (ARMS2).
89  We have conducted two genome-wide scans for age-related maculopathy using the Center for Inherited D
90                           Lesions typical of age-related maculopathy were determined by masked gradin
91                Lesions associated with early age-related maculopathy were distributed in specific pat
92        Various lesions associated with early age-related maculopathy were located in specific pattern
93 eas pigmentary abnormalities associated with age-related maculopathy were more prevalent in the super
94 cross different age groups, except for early age-related maculopathy, where older age increased the a
95  follow-up, a total of 279 incident cases of age-related maculopathy with vision loss to 20/30 or wor

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。